Brief: Cytrx Q3 loss $0.13/shr

LadRx

09/11/2016 14:00

Nov 9 (Reuters) - Cytrx Corp  CYTR.O  
    * Cytrx reports third quarter 2016 financial results 
    * Q3 loss per share $0.13 
    * Cytrx Corp - during Q3, embarked on a plan to reduce 
spending until additional results from Aldoxorubicin phase 3 STS 
clinical trial are available 
    * Cytrx- Reduction in spending included reducing headcount, 
stopping pre-commercialization activities for Aldoxorubicin, 
suspending further devt of DK049 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nPnNxkp2a 
Further company coverage:  CYTR.O  
 
 ((bangalore.newsroom@thomsonreuters.com;))